0.68 - 0.75
0.33 - 0.86
18.36M / 4.66M (Avg.)
34.50 | 0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.28%
Revenue growth under 50% of 0819.HK's 36.38%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
8.80%
Gross profit growth under 50% of 0819.HK's 22.41%. Michael Burry would be concerned about a severe competitive disadvantage.
85.33%
EBIT growth above 1.5x 0819.HK's 16.45%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
85.33%
Operating income growth above 1.5x 0819.HK's 16.45%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
87.44%
Net income growth above 1.5x 0819.HK's 26.98%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
62.43%
EPS growth above 1.5x 0819.HK's 25.00%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
62.43%
Diluted EPS growth above 1.5x 0819.HK's 25.00%. David Dodd would see if there's a robust moat protecting these shareholder gains.
15.43%
Share count expansion well above 0819.HK's 1.93%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
15.37%
Diluted share count expanding well above 0819.HK's 1.78%. Michael Burry would fear significant dilution to existing owners' stakes.
-100.00%
Dividend reduction while 0819.HK stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-698.01%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-308.72%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
11795.63%
10Y revenue/share CAGR above 1.5x 0819.HK's 2566.10%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
-12.09%
Negative 5Y CAGR while 0819.HK stands at 634.68%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-5.77%
Negative 3Y CAGR while 0819.HK stands at 100.97%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-9561.15%
Negative 10Y OCF/share CAGR while 0819.HK stands at 2151.57%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-664.88%
Negative 5Y OCF/share CAGR while 0819.HK is at 2635.95%. Joel Greenblatt would question the firm’s operational model or cost structure.
-1361.38%
Negative 3Y OCF/share CAGR while 0819.HK stands at 1067.10%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
233.13%
Below 50% of 0819.HK's 512.50%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
384.15%
5Y net income/share CAGR above 1.5x 0819.HK's 115.81%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-14.85%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
149.37%
5Y equity/share CAGR above 1.5x 0819.HK's 68.43%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
62.96%
3Y equity/share CAGR above 1.5x 0819.HK's 7.35%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-100.00%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
-18.74%
Firm’s AR is declining while 0819.HK shows 48.35%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
30.58%
We show growth while 0819.HK is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-2.55%
Negative asset growth while 0819.HK invests at 7.67%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
0.59%
Under 50% of 0819.HK's 12.76%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-99.86%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-35.78%
Our R&D shrinks while 0819.HK invests at 35.12%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-46.41%
We cut SG&A while 0819.HK invests at 17.48%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.